Emerald Health Pharmaceuticals (EHP) is a clinical-stage biotechnology company with a portfolio of novel, patented new chemical entities (NCEs), which in preclinical studies, have demonstrated the potential to be disease-modifying in various neurodegenerative, autoimmune, inflammatory, and fibrotic diseases with significant unmet medical need.

The company has created two families of new chemical entities, derived from synthetic cannabidiol (CBD) and cannabigerol (CBG). These molecules have been created through rational drug design to modulate specific receptors and physiological pathways in the body, which are validated targets in many serious diseases.  With a multi-pronged mechanism of action (MOA), these NCEs are well positioned as first-in-class disease-modifying therapeutic drug candidates for many diseases, which currently have no cure.

Driven by eminent global researchers in science and biotechnology, EHP has assembled a highly experienced and expert management team, supported by clinical and scientific advisory boards, to successfully develop these pharmaceutical drug product candidates.